ARS Pharmaceuticals, Inc. (SPRY)
Nasdaq · Healthcare · Biotechnology
$4.29+5.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $427M
- 52-week range
- $3.99 – $13.15
- 52-week change
- −60.37%
- EPS (trailing)
- −$2.18
- Next earnings
- Nov 10, 2026
Fiscal year to Dec 2025
- Revenue
- $84.3M (−5.46%)
- Net income
- −$171M
- Operating margin
- −212.9%
- Diluted EPS
- −$1.74
- Free cash flow
- −$171M
From the company’s annual report on SEC EDGAR.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 195 employees · ars-pharma.com